Sai Parenterals Ltd (SAIPARENT) is currently trading at 511.65 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sai Parenterals Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.

Over the past 52 weeks, Sai Parenterals Ltd has traded between a low of ₹400.00 and a high of ₹705.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sai Parenterals Ltd has a market capitalization of approximately 2,257.34. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sai Parenterals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 142.51 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,257.34 Cr, Sai Parenterals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sai Parenterals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sai Parenterals Ltd is 142.51. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Exchange filings put the renewed agreement at AUD 202 million, which the company said is about ₹1,300 crore over a 7.5-year term.

Sai Parenterals disclosed the renewed agreement value as AUD 202 million, which it approximated at about ₹1,300 crore in its exchange filings.

Standalone net profit was ₹88.75 million for the quarter ended June 30, 2026, while consolidated net profit after tax was ₹79.23 million.

The deal is valued at AUD 202 million, disclosed as about ₹1,300 crore, and runs for an initial 7.5 years with an option to extend by 3 more years by mutual consent.